Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 23
Filter
1.
Chinese Journal of Hematology ; (12): 742-748, 2023.
Article in Chinese | WPRIM | ID: wpr-1012223

ABSTRACT

Objective: To investigate the clinical characteristics, cytogenetics, molecular biology, treatment, and prognosis of patients with therapy-related myelodysplastic syndrome and acute myeloid leukemia (t-MDS/AML) secondary to malignancies. Methods: The clinical data of 86 patients with t-MDS/AML in West China Hospital of Sichuan University between January 2010 and April 2023 were retrospectively analyzed. The clinical characteristics, primary tumor types, and tumor-related therapies were analyzed. Results: The study enrolled a total of 86 patients with t-MDS/AML, including 67 patients with t-AML, including 1 patient with M(0), 6 with M(1), 27 with M(2), 9 with M(3), 12 with M(4), 10 with M(5), 1 with M(6), and 1 with M(7). Sixty-two patients could be genetically stratified, with a median overall survival (OS) of 36 (95% CI 22-52) months for 20 (29.9%) patients in the low-risk group and 6 (95% CI 3-9) months for 10 (14.9%) in the intermediate-risk group. The median OS time was 8 (95% CI 1-15) months in 32 (47.8%) patients in the high-risk group. For patients with non-acute promyelocytic leukemia (APL) and AML, the median OS of the low-risk group was 27 (95% CI 18-36) months, which was significantly longer than that of the non-low-risk group (χ(2)=5.534, P=0.019). All 9 APL cases were treated according to the initial treatment, and the median OS was not reached, and the 1-, 2-, and 3-year OS rates were 100.0%, (75.0±6.2) %, and (75.0±6.2) % respectively. Of the 58 patients with non-APL t-AML (89.7%), 52 received chemotherapy, and 16 achieved complete remission (30.8%) after the first induction chemotherapy. The 1-, 2-, and 3-year OS rates of the non-APL t-AML group were (42.0 ± 6.6) %, (22.9±5.7) %, and (13.4±4.7) %, respectively. The median OS of patients who achieved remission was 24 (95% CI 18-30) months, and the median OS of those who did not achieve remission was 6 (95% CI 3-9) months (χ(2)=10.170, P=0.001). Bone marrow CR was achieved in 7 (53.8%) of 13 patients treated with vineclar-containing chemotherapy, with a median OS of 12 (95% CI 9-15) months, which was not significantly different from that of vineclar-containing chemotherapy (χ(2)=0.600, P=0.437). In 19 patients with t-MDS, the 1-, 2-, and 3-year OS rates were (46.8±11.6) %, (17.5±9.1) %, and (11.7±9.1) % with a median OS of 12 (95% CI 7-17) months, which was not significantly different from that in t-AML (χ(2)=0.232, P=0.630) . Conclusions: Breast cancer, bowel cancer, and other primary tumors are common in patients with t-MDS/AML, which have a higher risk of adverse genetics. Patients with APL had a high induction remission rate and a good long-term prognosis, whereas patients without APL had a low remission rate and a poor long-term prognosis.


Subject(s)
Humans , Retrospective Studies , Leukemia, Myeloid, Acute/drug therapy , Leukemia, Promyelocytic, Acute/therapy , Prognosis , Myelodysplastic Syndromes/drug therapy , Neoplasms, Second Primary/drug therapy , Remission Induction , Antineoplastic Combined Chemotherapy Protocols/therapeutic use
2.
Article in Spanish | LILACS, CUMED | ID: biblio-1341403

ABSTRACT

Introducción: La leucemia promielocítica presenta particularidades biológicas y clínicas con respecto al resto de las leucemias mieloides agudas. El descubrimiento de los detalles moleculares de su patogénesis, posibilitó que su tratamiento, constituya una de las mejores representaciones de la investigación traslacional y esto hace que establezca un modelo para el desarrollo de terapias dirigidas a dianas moleculares con enfoque curativo en pacientes con cáncer. Objetivo: Abordar los principales avances en la terapia de la LPM desde el descubrimiento de los agentes diferenciadores hasta su estado actual. Métodos: Se realizó una búsqueda exhaustiva en bases de datos como Scielo, Pubmed, ScienceDirect, Redalyc y se utilizaron como referencias los artículos actualizados publicados principalmente en los últimos cinco años. Análisis y síntesis de la información: Se abordaron los principales avances en la terapia de este tipo de leucemia, desde el descubrimiento de los agentes diferenciadores hasta su estado actual, haciendo énfasis en su mecanismo de acción y nuevas opciones terapéuticas. Conclusiones: Los aportes realizados en el estudio etiopatogénico y molecular de la leucemia promielocítica y su impacto objetivo en la investigación clínica, constituyen uno de los mejores ejemplos de tratamiento dirigido a alteraciones moleculares específicas y representa un modelo de integración biológica, clínica y terapéutica en beneficio de los pacientes afectados con esta enfermedad(AU)


Introduction: Acute promyelocytic leukemia is a biologically and clinically different type from other acute myeloid leukemias. The discovery of molecular details in its pathogenesis enabled its treatment to constitute one of the best examples of translational research and makes a model for the development of targeted therapies with a curative approach in cancer patients. Objective: To analize the main advances in PML therapy from the discovery of differentiating agents to their current state. Methods: An exhaustive search was carried out in the databases as Scielo, Pubmed, ScienceDirect, Redalyc, and updated articles published mainly in the last five years were used as references. Analysis and synthesis of the information: The article addressed the main advances in the therapy of this type of leukemia, from the discovery of differentiating agents to its current state, emphasizing its mechanism of action and new therapeutic options. Conclusions: The contributions made in the etiopathogenic and molecular study of promyelocytic leukemia and its objective impact on clinical research constitute one of the best examples of treatment aimed at specific molecular alterations and represents a model of biological, clinical and therapeutic integration in benefit of patients affected with this disease(AU)


Subject(s)
Humans , Leukemia, Promyelocytic, Acute/therapy , SUMO-1 Protein , Translational Research, Biomedical
3.
Rev. cuba. hematol. inmunol. hemoter ; 37(1): e1249, ene.-mar. 2021. tab, graf
Article in Spanish | LILACS, CUMED | ID: biblio-1251713

ABSTRACT

Introducción: Con el protocolo LPM-TOA para tratamiento de la leucemia promielocítica, se han obtenido excelentes resultados, ya que se logra sobrevida global prolongada y posible curación de los enfermos. En la inducción se utilizan dos drogas cardiotóxicas: las antraciclinas y el trióxido de arsénico y en la consolidación los enfermos reciben una dosis elevada de arsénico. Objetivo: Evaluar la toxicidad cardíaca tardía en pacientes con leucemia promielocítica tratados según el protocolo LPM-TOA. Métodos: Se realizó un estudio observacional descriptivo, prospectivo y longitudinal que incluyó 20 pacientes tratados con protocolo LPM-TOA, seguidos en consulta entre enero y julio 2019. Los pacientes tenían más de dos años de haber recibido las drogas cardiotóxicas. Se revisaron las historias clínicas y se determinó la fracción de eyección ventricular izquierda y la deformidad longitudinal global, mediante ecocardiograma. Resultados: Se presentaron hombres y mujeres con igual frecuencia, edad promedio 41,5 ± 11,0 años. Durante la inducción, en menos de la mitad de los enfermos se suspendió el arsénico por elevación del segmento QT corregido; en la mayoría solo se suspendió por uno o dos días. La mayor parte de los pacientes tuvo la fracción de eyección ventricular izquierda con valores entre 61 y 70 por ciento y la deformidad longitudinal global fue - 24 - 22 por ciento Conclusiones: En los pacientes estudiados, el tiempo de haber recibido el trióxido de arsénico y la dosis recibida, no influyó en la función cardíaca(AU)


Introduction: The PML-ATO protocol for the treatment of promyelocytic leukemia has obtained excellent results, achieving high overall survival rates and the possible healing of patients. Two cardiotoxic drugs are used in the induction process: anthracyclines and arsenic trioxide, whereas during consolidation patients receive a high dose of arsenic. Objective: Evaluate the late cardiotoxicity in patients with promyelocytic leukemia treated by the PML-ATO protocol. Methods: An observational prospective longitudinal descriptive study was conducted of 20 patients treated with the PML-ATO protocol and followed-up in outpatient consultation from January to July 2019. More than two years had elapsed since the patients received the cardiotoxic drugs. A review was carried out of the patients' medical records and echocardiographic determination was made of left ventricular ejection fraction and overall longitudinal deformity. Results: Men and women presented the same frequency; mean age was 41.5 ± 11.0 years. During induction, arsenic was suspended in less than half the patients due to corrected QT elevation. In most it was only suspended for one or two days. Most patients had left ventricular ejection fraction values between 61 percent and 70 percent, whereas overall longitudinal deformity was - 24 percent - 22 percent. Conclusions: In the patients studied, cardiac function was not affected by the time elapsed since arsenic trioxide administration or the dose received(AU)


Subject(s)
Humans , Leukemia, Promyelocytic, Acute/mortality , Leukemia, Promyelocytic, Acute/therapy , Anthracyclines , Arsenic Trioxide/therapeutic use , Medical Records , Survival Rate , Cardiotoxicity/drug therapy
4.
Hematol., Transfus. Cell Ther. (Impr.) ; 43(1): 21-27, Jan.-Mar. 2021. tab, graf
Article in English | LILACS | ID: biblio-1154299

ABSTRACT

ABSTRACT Acute promyelocytic leukemia is a subtype of acute myeloid leukemia, characterized by the presence of neoplastic promyelocytes, due to the reciprocal balanced translocation between chromosomes 15 and 17. Currently, with the use of agents that act directly on this molecular change, such as all-trans retinoic acid and arsenic trioxide, APL has shifted from a highly mortal to a curable disease. However, some cases are still at high risk of death, especially early death, and acquiring a better understanding of the clinical and biological factors involving APL is needed to correctly identify and treat such cases. The early suspected diagnosis and prompt initiation of the target therapy are important for better response rates. The follow-up and outcomes, using real-life data from 44 consecutive APL patients, were studied between 2001 and 2013. The overall survival rate was 82.7% and early death was 16%. Almost all patient deaths were due to severe bleeding, which was confirmed by multivariate analysis, as the most important prognostic factor leading to death. A better understanding the pathogenesis of the hemorrhagic complications in APL is needed, as well as the risk factors associated with early death in APL patients, as this has become synonymous with overall mortality.


Subject(s)
Humans , Male , Female , Adolescent , Adult , Middle Aged , Leukemia, Promyelocytic, Acute/diagnosis , Leukemia, Promyelocytic, Acute/therapy , SUMO-1 Protein
5.
Chinese Journal of Hematology ; (12): 1008-1014, 2019.
Article in Chinese | WPRIM | ID: wpr-1012116

ABSTRACT

Objective: To investigate the clinical characteristics, diagnosis, treatment and prognosis of therapy-related myeloid neoplasms (t-MNs) after successful treatment for acute promyelocytic leukemia (APL) . Methods: Clinical data of 4 patients, diagnosed as t-MNs secondary to APL at Hematology Hospital of Chinese Academy of Medical Sciences from October 2012 to January 2019, were collected retrospectively. T-MNs related literature was reviewed. Results: The 4 cases were all females, with the median age 42 (range 40-53) years old at the diagnosis of APL. Regarding the induction and consolidation regimens, 3 patients received all-trans retinoid acid (ATRA) and arsenic trioxide (ATO) combined with anthracycline/anthraquinone and/or cytosine. One patient only received ATRA and other auxiliary drugs. Alkylating agents were not administrated. The 4 patients developed t-MNs 40 to 43 months after complete remission (CR) of APL, including 1 case of therapy-related myelodysplastic syndrome (t-MDS) and 3 cases of acute myeloid leukemia (t-AML) . The PML-RARα fusion genes were all negative when t-MNs developed. The three patients with t-AML were treated with 3 to 4 re-induction regimens, one of whom underwent allogeneic hematopoietic stem cell transplantation (allo-HSCT) after complete remission (CR) . One patient with t-MDS received hypomethylating agents. After a median follow-up of 54.5 (48-62) months, 2 patients with t-AML died, the median overall survival after t-MN was 12 (5-18) months. From 1989 to 2018, a total of 63 t-MN cases were reported in the literature. Therefore, 67 cases were analyzed when four patients in our center were added, including 27 males and 40 females with median age 52.5 (15-76) years. The median latency was 39 (12-126) months and the median overall survival after diagnosis of t-MN was 10 (1-39) months. Conclusions: Although rare, t-MNs may occur after successful control of APL. There are no existing guidelines for prevention and treatment of t-MNs, which have very poor prognosis. If cytopenia or other abnormalities of peripheral blood cells develop after 3 years of APL, t-MNs should be considered as a differential diagnosis.


Subject(s)
Adult , Female , Humans , Middle Aged , Antineoplastic Combined Chemotherapy Protocols , Arsenicals , Leukemia, Myeloid, Acute , Leukemia, Promyelocytic, Acute/therapy , Neoplasms, Second Primary , Oxides , Retrospective Studies , Treatment Outcome , Tretinoin
7.
Rev. bras. hematol. hemoter ; Rev. bras. hematol. hemoter;38(4): 285-290, Oct.-Dec. 2016. tab, graf
Article in English | LILACS | ID: biblio-829950

ABSTRACT

ABSTRACT Acute promyelocytic leukemia has good prognosis in view of the high complete remission and survival rates achieved with therapies containing all-trans retinoic acid or arsenic trioxide. However, there is a significant risk of death during induction due to hemorrhage secondary to disseminated intravascular coagulation. This has contributed to a gap in the prognosis of patients between developed and developing countries. The International Consortium on Acute Promyelocytic Leukemia was created in 2005 and proposed a treatment protocol based on daunorubicin and all-trans retinoic acid stratified by risk geared toward developing countries. Herein are presented the results from the first patient cohort treated in a single developing country hospital employing a slightly modified version of the International Consortium protocol in a real life setting. Twenty patients with acute promyelocytic leukemia were enrolled: 27.8% had low-risk, 55.6% intermediate risk and 16.7% high-risk. The complete remission rate was 94.4% after a median of 42 days. Both relapse rates and death rates were one patient (5.5%) each. No deaths were observed during consolidation. After a median follow-up of 29 months, the overall survival rate was 89.1%. Efficacy and safety of the International Consortium on Acute Promyelocytic Leukemia protocol has been reproduced in acute promyelocytic leukemia patients from a developing country.


Subject(s)
Leukemia, Promyelocytic, Acute/therapy , Clinical Protocols , Vascular Endothelial Growth Factor Receptor-1 , Health Consortia
8.
Actual. SIDA. infectol ; 24(90): 2-10, 20160000. fig, tab
Article in Spanish | LILACS, BINACIS | ID: biblio-1531714

ABSTRACT

El ácido all-transretinoico (ATRA) es uno de los mayores avan-ces en el tratamiento de las leucemias promielocíticas agudas (LPA). Con el uso asociado de quimioterapia y corticoides hacen de ésta leu-cemia las de mejor pronóstico hematológico con altas tasas de cu-ración. El ATRA es generalmente bien tolerado pero puede presen-tar efectos adversos sistémicos, englobados dentro del denominado sindrome ATRA (SATRA), o efectos directos gastrointestinales y mu-cocutáneos tales como las úlceras escrotales, transitorias y de buena respuesta clínica, tratándose de una entidad diferente al SATRA con presencia de vasculitis en el estudio anatomopatológico. En la revisión que realizáramos, hemos detectado 44 casos reportados en la literatu-ra a los que hemos agregado, en el siguiente documento, seis pacientes evaluados en nuestra institución con úlceras genitales asociadas al uso de ATRA, cuatro de ellos con presencia de vasculitis como lesión histo-lógica y un paciente con diagnóstico de síndrome Sweet


All-trans retinoic acid (ATRA) is one of the greatest advances in the treatment of Acute Promyelocytic Leukemia. The combination of all-trans-retinoic acid (ATRA), chemotherapy and corticoids has made acute promyelocytic leukemia (APL) a highly curable leukemia. The ATRA is generally well tolerated. Adverse effects, include ATRA syndrome (SATRA), and the gastrointestinal and mucocutaneous side effects, such us scrotal ulcers, wich are transitory and with a good clinical response. They are a different entity to SATRA, and presents vasculitis in the histological study. Of our knowledge, 44 cases were reported in the literature, we present the following document with six patients evaluated at our institution with genital ulcers associated with ATRA, four of them present vasculitis in pathological study, and one patient Sweet ́s Syndrome


Subject(s)
Humans , Male , Female , Adult , Scrotum/injuries , Tretinoin/therapeutic use , Vasculitis/therapy , Leukemia, Promyelocytic, Acute/therapy , Genitalia/injuries
9.
Rev. cuba. hematol. inmunol. hemoter ; 30(1): 1-3, ene.-mar. 2014.
Article in Spanish | LILACS | ID: lil-705657

ABSTRACT

Los avances científico-técnicos en el área de la medicina, principalmente los alcanzados en las últimas décadas del pasado siglo, han ayudado a realizar diagnósticos más precoces y precisos, y junto con la introducción de tratamientos novedosos, han hecho que cambie sustancialmente la historia natural y con ella la evolución y el pronóstico de varias enfermedades, así como la sobrevida y la calidad de vida de los pacientes. Dentro de las ciencias médicas, la hematología también ha sido beneficiada por estos avances. Los síndromes mielo y linfoproliferativos, los trastornos de la coagulación, las hemoglobinopatías, las gammapatías monoclonales, las leucemias agudas, etc., han sido favorecidas por estos logros. Sin embargo, la leucemia promielocítica (LPM), variedad M3 de las leucemias mieloides agudas según la clasificación del grupo franco-americano-británico, es sin dudas una de las enfermedades que ha tenido un cambio radical en cuanto a manejo, sobrevida e, incluso, posibilidades de curación de los pacientes. Esta variedad de leucemia pasó de ser una de las leucemias agudas más agresivas y de peor pronóstico por su alta mortalidad, a ser la leucemia mieloide de más fácil manejo y de mayor porcentaje de curación al lograrse, en un período relativamente corto, la remisión hematológica y molecular de los enfermos, todo ello gracias a la introducción de las técnicas de biología molecular y de terapias novedosas, como los inductores de la diferenciación...


Subject(s)
Humans , Technological Development/methods , Leukemia, Promyelocytic, Acute/diagnosis , Leukemia, Promyelocytic, Acute/drug therapy , Leukemia, Promyelocytic, Acute/therapy , Computational Biology/methods
11.
Rev. bras. hematol. hemoter ; Rev. bras. hematol. hemoter;34(2): 134-139, 2012. tab
Article in English | LILACS | ID: lil-624769

ABSTRACT

Acute promyelocytic leukemia is characterized by gene rearrangements that always involve the retinoic acid receptor alpha on chromosome 15. In the majority of patients t(15;17) is detected, which generates the promyelocytic leukemia gene/retinoic acid receptor alpha rearrangement. This rearrangement interacts with several proteins, including the native promyelocytic leukemia gene, thus causing its delocalization from the nuclear bodies, impairing its function. The immunofluorescence staining technique using the anti-PML antibody may be used to provide a rapid diagnosis and to immediately start therapy using all-trans retinoic acid. The experience of the International Consortium on Acute Promyelocytic Leukemia has demonstrated that early mortality was significantly reduced by adopting the immunofluorescence technique. All-trans retinoic acid combined with chemotherapy is the standard therapy; this promotes complete remission rates greater than 90% and cure rates of nearly 80%. However, early mortality is still an important limitation and hematologists must be aware of the importance of treating newly diagnosed acute promyelocytic leukemia as a medical emergency.


Subject(s)
Humans , Leukemia, Promyelocytic, Acute/diagnosis , Leukemia, Promyelocytic, Acute/epidemiology , Leukemia, Promyelocytic, Acute/therapy
12.
Journal of the Faculty of Medicine-Shaheed Beheshti University of Medical Sciences and Health Services. 2007; 31 (3): 233-239
in Persian, English | IMEMR | ID: emr-104696

ABSTRACT

Acute Promyelocytic Leukemia, APL, belongs to the group of acute myeloid leukemias. It is distinguished from other types of leukemia by distinct cell morphology, immuno-phenotyping characteristics, coagulopathy and different treatment modalities. The aim of this study was evaluation of the effects of cytologic, clinical and biologic factors specially CD34 expression in determining prognosis in patients with APL. In a descriptive retrospective analysis files of 60 patients with APL were reviewed and data statistically analyzed using SPSS soft ware with Chi Square and T- test. Complete remission and disease free survival [DFS] had no significant correlation with age, sex, WBC, Hemoglobin level, platelet count, purpura, CD34 status, and percentage of blasts in the bone marrow. There was no statistically significant correlation between CD34 expression with morphology, age, sex, WBC, platelet count, percentage of BM blasts and purpura. Cases with CD34 expression had severe anemia, [Hemoglobin=5.8 +/- 1.08], in comparison with patients with CD34 negative APL, [p=0.02]. Results of our study were not concordant with the literature, as recognized prognostic factors had no significant effect on the prognosis of our patients; therefore it is logical to believe that factors influencing the prognosis of APL in Iranian patients may be different. Failure in obtaining complete remission in all 4 patients with CD34+ APL indicates that presence of CD34+ may have been the cause of poor prognosis in these patients. Further studies are necessary to confirm this observation


Subject(s)
Humans , Leukemia, Promyelocytic, Acute/blood , Leukemia, Promyelocytic, Acute/therapy , Prognosis , Immunophenotyping , Antigens, CD34 , Retrospective Studies , Blood Coagulation Disorders , Remission Induction , Disease-Free Survival
13.
Rev. invest. clín ; Rev. invest. clín;57(3): 415-419, may.-jun. 2005. ilus
Article in English | LILACS | ID: lil-632461

ABSTRACT

The results of the treatment of 14 patients with promyelocytic leukemia (PML) treated with all trans-retinoic acid (ATRA), combined chemotherapy (CT) and prophylactic prednisone are reported; the median age was 30 years (range 7 - 49). A complete remission (CR) was obtained in 13 / 14 patients (93%). All patients were given ATRA fully as outpatients; the CR was achieved after the administration of ATRA in five patients, whereas in the remaining eight, CT was required to achieve it. There were no instances of the ATRA syndrome. One patient relapsed with a PML/RAR-a negative PML 575 days after achieving the CR, failed to respond again to ATRA and died. The median overall (OS) and disease free survival (DFS) has not been reached, being above 4,000 days, whereas the 12-month DFS was 93%, the three and five years DFS being 85%. The treatment employed differs from others in: Oral prednisone is used prophylactically, ATRA is given on an outpatient basis and adriamycin is used instead of other anthracyclines. The results are similar to those obtained in other centers worldwide and it is possible that the prophylactic administration of prednisone precluded the development of the full-blown ATRA syndrome in this group of patients.


Se informan los resultados del tratamiento en una sola institución de 14 pacientes con leucemia aguda promielocítica (LAPM) en quienes se empleó la combinación de ácido holotrans-retinoico (ATRA) quimioterapia combinada y prednisona profiláctica. La mediana de edad fue de 30 años (rango 7-49). Se obtuvo remisión completa (hematológica y molecular) (RC) en 13 pacientes (93%); a todos los pacientes se les administró el ATRA de manera ambulatoria. La RC se obtuvo con el ATRA en cinco pacientes; en los demás la RC se obtuvo después de habérseles administrado la quimioterapia con citarabina/adriamicina. No hubo ningún caso de síndrome de ATRA. Un paciente recayó con una LAPM PML/ RAR-a negativa, 575 días después de haber logrado la RC y falleció. Otro paciente recayó 20 meses después de haber logrado la RC y fue rescatado con el mismo esquema de tratamiento; permanece en segunda remisión molecular por más de seis años. La mediana de supervivencia (SV), tanto global como libre de recaídas de todo el grupo, no se ha alcanzado y es mayor de 4,000 días, en tanto que la SV a 12 meses fue de 93% y a tres y cinco años de 85%. El esquema de tratamiento usado difiere de otros en que se usa prednisona oral, se administra el ATRA de manera ambulatoria y se usa adriamicina y no otras antracidinas; los resultados son similares a los obtenidos con otros esquemas parecidos en otros sitios del mundo; es posible que el uso profiláctico de prednisona haya eliminado la ocurrencia del síndrome de ATRA.


Subject(s)
Adolescent , Adult , Child , Female , Humans , Male , Middle Aged , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Leukemia, Promyelocytic, Acute/drug therapy , Tretinoin/therapeutic use , Administration, Oral , /administration & dosage , Combined Modality Therapy , Cytarabine/administration & dosage , Disease-Free Survival , Doxorubicin/administration & dosage , Follow-Up Studies , Leukocyte Count , Life Tables , Leukemia, Promyelocytic, Acute/blood , Leukemia, Promyelocytic, Acute/therapy , Methotrexate/administration & dosage , Mexico/epidemiology , Neoplasm Proteins/blood , Oncogene Proteins, Fusion/blood , Peripheral Blood Stem Cell Transplantation , Prospective Studies , Prednisone/administration & dosage , Remission Induction , Transplantation, Autologous , Tretinoin/administration & dosage , Biomarkers, Tumor/blood
14.
Rev. argent. urol. (1990) ; 66(3): 141-143, jul.-ago. 2001. ilus
Article in Spanish | LILACS | ID: lil-307039

ABSTRACT

Presentamos el caso de un paciente con diagnótico de leucemia promielocítica agudo que desarrollo úlceras escrotales múltiples al ser tratado con ácido retinoico ("Vesanoid"). Al disminuir la dosis que estaba recibiendo, las úlceras se autolimitaron y resolvieron espontáneamente


Subject(s)
Humans , Male , Adult , Leukemia, Promyelocytic, Acute/therapy , Scrotum , Tretinoin , Ulcer , Skin Ulcer/therapy
16.
São Paulo med. j ; São Paulo med. j;118(6): 173-8, Nov. 2000. graf, tab
Article in English | LILACS | ID: lil-277625

ABSTRACT

CONTEXT: Young patients affected by acute myeloid leukemia (AML) achieve complete remission (CR) using conventional chemotherapy in about 55-85 percent. However, 30 percent of patients fail to achieve CR and the remission duration is often only about 12 months. More intensive treatment after CR seems to be necessary in order to maintain CR and obtain a definitive cure. In Brazil, few reports have been published on this important subject. OBJECTIVE: The aim of this study was to describe a Brazilian experience in the treatment of "de novo" acute myeloid leukemia (AML) in younger adult patients (age < 60 years). DESIGN: Retrospective analysis. SETTING: University Hospital, Hematology and Hemotherapy Center, State University of Campinas, Brazil...


Subject(s)
Humans , Male , Female , Adolescent , Adult , Middle Aged , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Leukemia, Myeloid/drug therapy , Remission Induction/methods , Brazil , Leukemia, Promyelocytic, Acute/drug therapy , Leukemia, Promyelocytic, Acute/therapy , Leukemia, Myeloid/therapy , Acute Disease , Survival Rate , Retrospective Studies , Follow-Up Studies , Bone Marrow Transplantation , Statistics, Nonparametric , Disease-Free Survival
18.
Rev. bras. hematol. hemoter ; Rev. bras. hematol. hemoter;22(supl.2): 179-181, 2000. tab
Article in Portuguese | LILACS | ID: lil-569575

ABSTRACT

Neste relato apresento os resultados de 51 pacientes portadores de leucemia mielóide aguda (39 leucemias primárias, 9 secundárias a síndrome mielodisplásica e 3 de origem indeteminada). Comparamos os resultados desta casuística com resultados anteriores do Serviço de Hematologia do HUCFF e observamos que a percentagem de casos de leucemia subtipo M3 elevou-se de 24 para 38 por cento dos casos e o número de pacientes que não receberam tratamento foi reduzido de 37 para 18 por cento. A taxa de remissão completa em ambas as casuísticas foi idêntica, 59 por cento e a sobrevida global não pode ser terminada devido à diferença do período de observação de 13 anos no primeiro trabalho, contra 5 anos no atual.


Subject(s)
Humans , Leukemia, Myeloid, Acute/therapy , Leukemia, Promyelocytic, Acute/therapy
20.
Rev. med. Tucumán ; 5(3): 153-8, jul.-sept. 1999. ilus
Article in Spanish | LILACS | ID: lil-263436

ABSTRACT

Se presenta el caso de una niña de 9 años, eutrófica, que ingresa con astenia, anorexia, hipertrofia gingival, hepatoesplenomegalia y petequia y hematomas. La citología de médula ósea es característica de Leucemia promielocítica aguda, confirmada por citoquímica y cariotipo con la característica translocación de brazos largos entre los cromosomas 15 y 17. A pesar de las graves complicaciones infecciosas que presentó, la respuesta terapéutica fue buena, hallándose en remisión hasta la actualidad.


Subject(s)
Humans , Female , Translocation, Genetic , Retinal Hemorrhage/diagnosis , Melena/diagnosis , Leukemia, Promyelocytic, Acute/complications , Leukemia, Promyelocytic, Acute/diagnosis , Leukemia, Promyelocytic, Acute/genetics , Leukemia, Promyelocytic, Acute/mortality , Leukemia, Promyelocytic, Acute/prevention & control , Leukemia, Promyelocytic, Acute/drug therapy , Leukemia, Promyelocytic, Acute/therapy , Bone Marrow Cells/cytology , Remission Induction/methods , Platelet Transfusion
SELECTION OF CITATIONS
SEARCH DETAIL